Imatinib is used as a frontline therapy for CML and imatinib is a selective inhibitor of tyrosine kinase that binds to the ATP-binding site of BCR-ABL gene. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.